# HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Source: https://onco.cc/trials/nct06383078/  
OnCo record `nct06383078` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), tegafur, gimeracil and oteracil (S-1), leucovorin (folinic acid) and other drugs in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.

## Summary

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT06383078 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 120 participants, started 2024-04-20 and due to reach its primary completion in 2027-03-01. Interventions recorded: HR070803; Oxaliplatin; Tegafur; Folinic acid; 5-Fluorouracil. Conditions listed: Efficacy and Safety. Primary outcome: 1-year Disease-free survival rate. Pancreatic eligibility wording from the registry: "Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06383078
- Phase: 2
- Setting: HR070803 in Combination With Oxaliplatin Plus Tegafur Versus HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate as Adjuvant Therapy for Pancreatic Cancer: A Multicenter, Multi-cohort, Randomized, Phase II Study
- Sponsor: The First Affiliated Hospital with Nanjing Medical University
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06383078: https://clinicaltrials.gov/study/NCT06383078

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06383078.json